Spark Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2013-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.sparktx.com
Clinical Trials
17
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
- Conditions
- Huntington Disease
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Spark Therapeutics, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT06826612
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸University of Cincinnati/Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Study of a Gene Therapy Treatment for Hemophilia A
- Conditions
- Hemophilia A
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Spark Therapeutics, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT06297486
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Loma Linda University Health, Loma Linda, California, United States
🇺🇸Orthopaedic Institute for Children/Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
- Conditions
- Glycogen Storage Disease Type IILysosomal Storage DiseasesGlycogen Storage Disease Type 2LOPDPompe DiseasePompe Disease (Late-onset)Acid Maltase Deficiency
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Spark Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04093349
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸University of California Irvine Health, Orange, California, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease
- Conditions
- Lysosomal Storage DiseasesGlycogen Storage Disease Type 2LOPDPompe DiseasePompe Disease (Late-onset)Acid Maltase Deficiency
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Spark Therapeutics, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT03893240
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸University of California Irvine Health, Orange, California, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
- Conditions
- Blood Coagulation Disorders, InheritedHemorrhagic DisordersBlood Coagulation DisorderCoagulation Protein DisordersHemophilia AGenetic Diseases, InbornFactor VIII DeficiencyHematologic DiseasesGenetic Diseases, X-Linked
- Interventions
- Drug: Standard of Care FVIII Replacement therapy
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Spark Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03876301
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
- Prev
- 1
- 2
- 3
- 4
- Next